

## Technology Advisory Interests Register

**Topic: Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over  
[ID6394]**

**Publication Date: TBC**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Clare Offer	TAC Committee Member	Non-financial professional	I am a public health representative on the Clinical Reference Group for Allergy and Immunology as part of my NHSE day job. I have not had any specific involvement with or discussions about garadacimab.	21/05/2025 17/07/2025	It was agreed that Clare's declaration would not prevent them from participating in discussions on this appraisal
Elizabeth Thurgar	TAC Committee Member	Financial	I am currently working with Takeda in an unrelated indication, central disorders of hypersomnolence.	17/07/2025	It was agreed that Elizabeth's declaration would not prevent them from participating in discussions on this appraisal
Satish Venkateshan	TAC Committee Member	Financial	Regeneron is developing therapeutics for a broad range of diseases including REGN9533 targeting Factor XII and ALN-F1202 targeting Factor XII in collaboration with Alnylam. I work for Regeneron, pharmaceuticals/biotech company. I also own shares in the company and have stock options.	21/05/2025 18/07/2025	It was agreed that Satish's declaration would prevent them from participating in discussions on this appraisal

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Scott Hackett	Expert	Financial	<ul style="list-style-type: none"> <li>I have received sponsorship from Takeda to attend a meeting and to lecture.</li> <li>I received payment as an expert advisor to BioCryst for advice on Berotralstat granule formulation and how this fits into the treatment algorithms.</li> <li>I have received sponsorship from Pharming and BioCryst to attend meetings.</li> <li>I have received sponsorship from Pharming to attend the 2025 EAACI conference.</li> <li>I have provided expert immunology advice to the Clinical Reference Group and Lead Commissioner for NHS England which is my nominating organisation.</li> <li>I am the paediatric advisor to HAE UK.</li> <li>I met with the CSL Behring team for clarification.</li> </ul>	03/10/2024 12/08/2025	It was agreed that Scott's declaration would not prevent them from providing expert advice to the committee
Sorena Kiani-Alikhan	Expert	Financial	<ul style="list-style-type: none"> <li>I have taken part as a panel member in webinars organised by Takeda and acted in an advisory capacity helping to develop educational material for</li> </ul>	26/09/2024 12/08/2025	It was agreed that Sorena's declaration would not prevent them from providing expert advice to the committee

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>HCP. Takeda is my nominating organisation.</p> <ul style="list-style-type: none"> <li>I have been chief and principal investigator for studies and been in receipt of honorarium for consulting work and advisory boards organised by CSL Behring, BioCryst, Pharming and Takeda.</li> <li>My department has received a grant from Takeda to develop our IT systems.</li> <li>I met with the CSL Behring team for clarification.</li> </ul>		
Angela Metcalfe	Expert	Financial	<ul style="list-style-type: none"> <li>My nominating organisation, HAE UK, has received unrestricted grants from CSL Behring, BioCryst, Pharming and Takeda.</li> <li>HAE UK has had discussions with CSL Behring to understand the product.</li> </ul>	20/01/2025 12/08/2025	It was agreed that Angela's declaration would not prevent them from providing expert advice to the committee
Tim Crouch	Expert		I am a Trustee of HAE UK.	03/02/2025 12/08/2025	It was agreed that Tim's declaration would not prevent them from providing expert advice to the committee

DRAFT